OptimizeRx Corporation - OPRX STOCK NEWS

OptimizeRx Corp (Nasdaq: OPRX), a healthcare technology solutions provider, has announced its participation in two upcoming investor conferences in New York City. The company will attend the 13th Annual ROTH Technology Conference from November 19th-20th, 2024, at The Hard Rock Hotel, and Canaccord Genuity's 2024 CG MedTech, Diagnostics and Digital Health & Services Forum on November 21st, 2024, at The Westin NY Grand Central. Both events will feature one-on-one meeting formats with management.

OptimizeRx reported Q3 2024 financial results with revenue increasing 30% year-over-year to $21.3 million. Gross profit rose 37% to $13.4 million with a 63% margin. The company reported a GAAP net loss of $(9.1) million, while non-GAAP net income was $2.3 million. Adjusted EBITDA improved to $2.7 million from $0.9 million year-over-year. The company updated its 2024 guidance, expecting revenue between $88-92 million and Adjusted EBITDA of $8-10 million. Cash position strengthened to $16.1 million as of September 30, 2024.

OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of healthcare technology solutions, has scheduled its third quarter 2024 conference call for November 13, 2024, at 4:30 p.m. Eastern Time. The company will discuss financial results for the quarter ended September 30, 2024, which will be released before the call. Management will host the call followed by a Q&A session. The call will be accessible via toll-free and international numbers, with a webcast option available. A replay will be accessible for 12 months through the company's investor relations website.

OptimizeRx Corp. (Nasdaq: OPRX) has expanded its strategic relationship with a major pharma client, resulting in a multi-solution, multi-brand program with a total in-year commitment of over $10 million. This includes the previously mentioned $6 million DAAP contract, which is still undergoing internal review. The expansion demonstrates the value of OptimizeRx's solutions in driving stronger commercial performance through HCP and DTC marketing alignment.

Key highlights:

• Top 20 pharma clients now average $2.7 million in revenue per client
• Top 3 clients contribute $9.7 million in revenue
• Organic growth remains a key driver for the business
• The company is leveraging its omni-channel platform powered by AI-targeted reach

OptimizeRx Corp. (Nasdaq: OPRX) has launched Micro-Neighborhood® Targeting (MNT) on its Dynamic Audience Activation Platform (DAAP), enhancing Direct-to-Consumer (DTC) marketing for healthcare audiences. This AI-driven technology enables pharmaceutical brands to deliver synchronized DTC and healthcare professional (HCP) campaigns, predicting brand eligibility within the U.S. population.

Key features of DAAP include:

• AI-predicted brand eligibility signals for precise timing of point-of-care messaging
• Integration of real-world data through advanced machine learning models
• Personalized brand communications across various media channels
• Privacy-compliant connection of consumer and clinical data

The platform has demonstrated an average script lift of 25% in HCP audiences over the past three years, offering a more streamlined approach to reach specific patient and provider segments.

OptimizeRx Corp (Nasdaq: OPRX) reported its Q2 2024 financial results, highlighting significant growth despite some challenges. Revenue increased by 36% year-over-year to $18.8 million, while gross profit surged 50% to $11.7 million with a gross margin of 62%. The company secured eight new DAAP deals in Q2. However, GAAP net loss remained at $(4.0) million, slightly improved from $(4.1) million in Q2 2023. Non-GAAP net income was $0.3 million, or $0.02 per diluted share, compared to a non-GAAP net loss of $(0.2) million, or $(0.01) per diluted share, in the year-ago period. Adjusted EBITDA turned positive at $0.5 million from $(0.8) million. Cash holdings increased to $15.0 million as of June 30, 2024. The company reiterated its 2024 guidance for revenue of at least $100 million and Adjusted EBITDA of $11 million. Notable was a timing issue with a $6 million DAAP deal that impacted expected revenues.

OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of healthcare technology solutions, has announced its upcoming second quarter 2024 conference call. The call is scheduled for August 8, 2024, at 4:30 p.m. Eastern Time. Financial results for the quarter ended June 30, 2024, will be released prior to the call. The company's management will host the call, followed by a Q&A session.

Investors and interested parties can join the call using the provided toll-free and international numbers, or access the webcast via the given link. A replay of the call will be available for 12 months through the Investors section of OptimizeRx's website.

OptimizeRx Corp. (Nasdaq: OPRX) has announced its continued commitment to helping pharmaceutical brands navigate the changing landscape of state-level consumer privacy legislation while executing nationwide marketing programs. The company's Micro Neighborhood® Targeting technology enables brands to maintain campaign scale and effectiveness while complying with evolving regulations.

Key points:

• Nearly 50% of the US population is currently covered by state-level consumer data protection regulations, expected to grow to 62% in the next 18 months.
• OptimizeRx's solutions help pharmaceutical marketers maintain campaign scale, reach hard-to-target patient populations, and ensure privacy-safe data handling.
• The company's Dynamic Audience Activation Platform (DAAP) offers privacy-by-design techniques and tailored predictive marketing strategies.

OptimizeRx has announced impressive results from an internal marketing study comparing their AI-guided Dynamic Audience Activation Platform (DAAP) to traditional trigger-based marketing for a Major Depressive Disorder (MDD) therapy. The study revealed that DAAP:

- Identified nearly 3 times more brand-eligible patients per HCP per month
- Delivered 33% higher script lift per HCP per month
- Produced a 75% increase in ROI

These results were achieved in just 3 months, compared to the 6-month trigger-based campaign. The study demonstrates DAAP's superior effectiveness in reaching complex-to-diagnose-and-treat audiences, challenging the status quo of pharma marketing.